Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study
2007

Study on Sirolimus for Polycystic Kidney Disease

Sample size: 100 publication Evidence: moderate

Author Information

Author(s): Serra Andreas L, Kistler Andreas D, Poster Diane, Struker Marian, Wüthrich Rudolf P, Weishaupt Dominik, Tschirch Frank

Primary Institution: University Hospital, Zürich, Switzerland

Hypothesis

Can sirolimus effectively retard kidney volume growth in patients with autosomal dominant polycystic kidney disease (ADPKD)?

Conclusion

The study aims to determine if sirolimus can effectively slow down kidney volume growth in patients with ADPKD.

Supporting Evidence

  • Sirolimus has shown effectiveness in reducing cyst growth in animal models of polycystic kidney disease.
  • The study is the first clinical trial to examine sirolimus in young patients with early manifestations of ADPKD.
  • Kidney volume growth is a predictor of renal functional decline in ADPKD patients.

Takeaway

This study is testing if a medicine called sirolimus can help kids and young adults with a kidney disease called ADPKD by stopping their kidneys from getting bigger.

Methodology

This is a single center, randomized controlled, open label trial assessing the effect of sirolimus on kidney volume growth in ADPKD patients.

Potential Biases

Potential bias in patient selection due to the focus on a specific age group and family history.

Limitations

The study is limited to a single center and may not be generalizable to all ADPKD patients.

Participant Demographics

Patients aged 18-40 years with preserved renal function and documented kidney volume growth.

Digital Object Identifier (DOI)

10.1186/1471-2369-8-13

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication